Nivolumab (Second-line squamous cell oesophageal carcinoma): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo® Page last updated: 1 July 2022 Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 464KB) Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 86KB)